Genetic factors and risk of persistent pulmonary hypertension in newborns

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the association between genetic variations in the PTGS1 gene and the risk of persistent pulmonary hypertension of the newborn (PPHN) related to in utero exposure to non-steroidal anti-inflammatory drugs (NSAIDs). The study will compare the incidence of PTGS1 genetic variants in infants diagnosed with PPHN to healthy control infants. By analyzing the genetic sequences, the researchers hope to identify specific variations that may increase susceptibility to ductal constriction and PPHN. This research could provide insights into the biological mechanisms underlying PPHN and its association with NSAID exposure during pregnancy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and normal, healthy infants born greater than or equal to 34 weeks gestational age.

Exclusion Criteria:

* Patients will be excluded if they are diagnosed with lethal congenital anomalies
* structural congenital heart disease except presence of patent ductus arteriosus (PDA) or patent foramen ovale
* structural gastrointestinal tract abnormality that could interfere with meconium passage
* congenital anomalies such as diaphragmatic hernia, Potter's syndrome, or pulmonary hypoplasia

Where it's running

• Children's Wisconsin
  Milwaukee, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: G. Ganesh Konduri, MD — Medical College of Wisconsin
• Study coordinator: G. Ganesh Konduri, MD
• Email: gkonduri@mcw.edu
• Phone: 414-266-6820

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Closed-loop smart weaning of inhaled nitric oxide for newborns with PPHN

  We're testing an automated closed-loop system to wean inhaled nitric oxide in newborns with persistent pulmonary hypertension (PPHN) to see if it standardizes the process and reduces staff workload.

  Recruiting Children's Hospital of Fudan University · Shanghai · NCT06832163

• Melatonin plus inhaled nitric oxide for pulmonary hypertension in full-term newborns

  This study tests whether adding melatonin to inhaled nitric oxide helps treat pulmonary hypertension in full-term neonates.

  Recruiting Ain Shams University · Cairo, Abbassia · NCT07850934

• Treprostinil for newborns with persistent pulmonary hypertension

  This observational project will see if treprostinil used in newborns with persistent pulmonary hypertension appears safe and helpful when used in routine care in French hospitals.

  Recruiting at 4 sites Ferrer Internacional S.A. · Bron and 3 other locations · NCT06499363

• Nebulized magnesium sulfate and sildenafil for treating newborns with severe pulmonary hypertension

  This study is testing if a mix of nebulized magnesium sulfate and sildenafil can help newborns with severe pulmonary hypertension who are on breathing machines feel better compared to just using sildenafil alone.

  Recruiting Phase 1/2 Sohag University · Sohag · NCT04898114

• Dopamine versus norepinephrine for low blood pressure in newborns with pulmonary hypertension

  This pilot test compares norepinephrine and dopamine as the first medicine to raise blood pressure in term and late‑preterm newborns with pulmonary hypertension and hypoxemic respiratory failure.

  Recruiting Phase 4 University of California, Davis · Sacramento, California · NCT07322133

• Observing the use of a Nitric Oxide Generator for newborns with pulmonary hypertension

  This study is testing if a special device that delivers nitric oxide can help newborns with pulmonary hypertension breathe better and improve their health.

  Recruiting Novlead Inc. · Guangzhou, Guangzhou · NCT05703191

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.